A Phase 1 study of VX-445 to evaluate single ascending doses, multiple ascending doses and triple combination dosing with the tezacaftor/ivacaftor combination in healthy volunteers.

Trial Profile

A Phase 1 study of VX-445 to evaluate single ascending doses, multiple ascending doses and triple combination dosing with the tezacaftor/ivacaftor combination in healthy volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 May 2017

At a glance

  • Drugs VX 445 (Primary) ; Ivacaftor/tezacaftor
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top